Summary & Overview
HCPCS Level II C9254: Lacosamide Injection, 1 mg
HCPCS Level II code C9254 denotes a 1 mg injectable dose of lacosamide, an antiepileptic drug administered parenterally. Nationally, accurate coding for injectable antiseizure medications matters for clinical documentation, billing accuracy, and appropriate claims processing across payers. This code specifically identifies the drug itself at a unit dose level, which informs billing for administered quantities and supports pharmacy and infusion service workflows.
Key payers in the national landscape include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical sites of service, and what to expect in payer handling and claims submission. The publication also summarizes relevant benchmarks where available, common modifier patterns, and clinical context regarding lacosamide as an antiepileptic agent.
The article provides practical reference material for coding and billing professionals, revenue cycle staff, and clinical pharmacists: a clear definition of the code, the service environment in which it is used, and pointers to areas where policy updates or payer-specific requirements may affect reimbursement processing. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code C9254 represents an injection formulation of lacosamide, 1 mg. The service type is drug administration (injectable antiepileptic agent) delivered as a parenteral pharmaceutical product. The typical site of service for this code is outpatient infusion or clinic-based injection, including ambulatory infusion centers and outpatient hospital departments.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult or pediatric patient with focal-onset seizures or another neurologic indication for intravenous antiepileptic therapy who requires inpatient or outpatient parenteral administration of lacosamide. The patient may present to the emergency department with breakthrough seizures while already on oral antiseizure medications, to an infusion center for loading or transition from oral to parenteral therapy, or to a hospital medical-surgical or neurology unit for dose titration when oral administration is not feasible (for example, due to vomiting, altered mental status, or perioperative NPO status).
Clinical workflow:
-
The neurology or emergency medicine clinician documents the indication and orders
C9254as part of the medication administration record with the prescribed dose in milligrams. -
Pharmacy verifies dosing, prepares the intravenous lacosamide syringe or bag per institutional protocols, and applies appropriate compounding documentation.
-
Nursing administers the injection or IV push/infusion per facility policy, monitors vital signs and neurologic status during and after administration, and documents the procedure and any immediate adverse reactions.
-
Billing staff assign
C9254to report the administered quantity (per1 mgunits) and append relevant modifier(s) to reflect clinical circumstances, payer requirements, or drug wastage, as indicated by payer policy and facility documentation. -
Clinical documentation includes the reason for parenteral administration, route, dose, time, patient tolerance, and concurrent medications to support medical necessity for the injectable formulation.